Irazú Oncology’s development pipeline is built on a novel OMV-based platform designed to overcome key barriers in cancer immunotherapy.
Design
Preclinical
Phase 1
Phase 2
Phase 3
IRZ-01
MUC1 and CEA Tumor Antigens
IRZ-01, our lead product candidate, showcases our OMV platform technology by precisely targeting tumor antigens across multiple solid tumor types including colorectal, endometrial, and gastric cancers. In preclinical studies, it achieved complete tumor remissions and generated protective immune responses against recurrence, with size-optimization for efficient lymph node delivery and compatibility with existing treatments like checkpoint inhibitors.